Skip to content

The Impact of Continuous Glucose Monitoring on Maternal and Infant's Outcomes in Gestational Diabetes

The Impact of Continuous Glucose Monitoring on Maternal and Infant's Outcomes in Gestational Diabetes: Testing the Moderating Effects of Socioeconomic and Cultural Factors

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06436326
Enrollment
120
Registered
2024-05-31
Start date
2024-08-22
Completion date
2027-12-31
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Continuous Glucose Monitoring, Gestational Diabetes Mellitus

Keywords

Gestational Diabetes Mellitus, Continuous Glucose Monitoring, Health Interventions

Brief summary

This study will discuss the impact of continuous glucose monitoring on maternal and infant's outcomes in gestational diabetes mellitus, and test the moderating effect of socioeconomic and cultural factors (dietary habits, socioeconomic status and income).

Detailed description

Background: The global prevalence of gestational diabetes mellitus is increasing. To reduce the negative impact of gestational diabetes mellitus on maternal and fetal health, managing blood glucose during pregnancy is important, which also shows the importance of blood glucose monitoring. Continuous glucose monitoring (CGM) is different from traditional blood glucose meters (BGM). Continuous glucose monitoring is now known to have good control effects in type 1 and type 2 diabetes mellitus. However, there are still few randomized controlled trials for gestational diabetes mellitus and there are not consistent results. In addition, blood glucose management conditions vary among groups with different dietary habits, socioeconomic status and income. Food culture of Taiwan is diverse and it is easy to consume sugar or high carbohydrate foods. Continuous glucose monitoring can be more sensitive to measure glucose fluctuations, but it is still unknown whether it will have different maternal and infant health effects for groups whose glucose is prone to exceed the target range. Objective: To explore the impact of continuous glucose monitoring on the health outcomes of mothers and infants with gestational diabetes mellitus, and to test the moderating effect of socioeconomic and cultural factors (dietary habits, socioeconomic status and income) on the relationship between continuous glucose monitoring and the health outcomes among mothers with gestational diabetes mellitus and their infants. Methods: This study was a randomized controlled trial. It was expected that 120 pregnant women with gestational diabetes mellitus would be randomly assigned to the " Control group" (40 people) using blood glucose meters (BGM), or the "experimental group" (80 people) using continuous glucose monitoring (CGM) at a ratio of 1:2. In the "experimental group", they would be assigned to the " Experimental group1-Continuous glucose monitoring (CGM) group" (40 people) or the " Experimental group2-Continuous glucose monitoring (CGM) with nursing care group" (40 people). The " Experimental group2-Continuous glucose monitoring (CGM) with nursing care group " would provide nursing intervention during the perinatal period. The outcome variables of the three groups would be tracked and compared with 3 time points, which were 24 to 32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, and 4 to 12 weeks after delivery. The primary outcomes were maternal glycemic parameters, cardiometabolic risk factors, and fetal macrosomia. Secondary outcomes included gestational weight, depression and infant growth curve.

Interventions

DEVICEContinuous glucose monitor

Participants will receive a set of continuous glucose monitor (CGM) at "24-32 weeks of pregnancy (first set)" and "33 weeks of pregnancy to before delivery (second set)," respectively. CGM wearing instruction will be provided before the first wearing at "24-32 weeks of pregnancy". After completing the first wearing (approximately 14 days after starting to wear), the investigators will provide a glucose monitor report. The second CGM was worn from the 33rd week of pregnancy to before delivery, and another glucose monitor report was given approximately 14 days after starting to wear.

Individual nursing care and consultation for pregnant women with gestational diabetes mellitus, including glucose monitor suggestions, dietary suggestions, emotional support, breastfeeding support.

Participants are required to use blood glucose meters (BGM) at "24-32 weeks of pregnancy" and "33 weeks to before delivery". After 14 days of glucose monitoring at "24-32 weeks of pregnancy", a glucose monitor report will be given to the participants. After the 14 days of glucose monitoring at "33 weeks to before delivery ", another glucose monitor report will be given to the participants.

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Aged 18 years or above * Pregnant women diagnosed with gestational diabetes mellitus * Those who are willing to participate in this study

Exclusion criteria

* Those who have been diagnosed with diabetes mellitus "before pregnancy" * Those whose skin is likely allergic to some materials such as tapes (signs and symptoms such as redness, swelling, itching, painful, presenting blisters or rashes caused by wearing breathable tapes, patches, etc.) * Those who is with abnormal coagulation function

Design outcomes

Primary

MeasureTime frameDescription
Maternal Oral glucose tolerance test24-32 weeks of pregnancy, 4-12 weeks postpartumOral glucose tolerance test (OGTT) including fasting, 1-hour, and 2-hour glucose levels.
Maternal glycated albumin24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, 4-12 weeks postpartumglycated albumin
Maternal albumin24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, 4-12 weeks postpartumalbumin
Maternal fasting plasma glucose24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, 4-12 weeks postpartumfasting plasma glucose
Maternal insulin24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, 4-12 weeks postpartuminsulin
Total cholesterol24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, 4-12 weeks postpartumtotal cholesterol
Triglycerides24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, 4-12 weeks postpartumtriglycerides
High-density lipoprotein24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, 4-12 weeks postpartumhigh-density lipoprotein
Low-density lipoprotein24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, 4-12 weeks postpartumlow-density lipoprotein
Fetal macrosomia4-12 weeks postpartumFetal macrosomia is defined as a birth weight ≥4,000 g.

Secondary

MeasureTime frameDescription
Gestational weight gain24-32 weeks of pregnancy, 33 weeks of pregnancy to before deliveryGestational weight gain will be based on pre-pregnancy Body Mass Index (BMI) and classified according to the Institute of Medicine (IOM) recommendations.
Depression24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, 4-12 weeks postpartumEdinburgh Postnatal Depression Scale (EPDS) The EPDS is a 10-item questionnaire. Each item scores from 0-3. The total score is found by adding together the scores for each of the 10 items. The minimum is 0 and the maximum is 30. Scoring above 12 or 13 are likely to be suffering from depression.
Infant growth curve4-12 weeks postpartuminfant growth curve
Maternal average fasting plasma glucose24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, 4-12 weeks postpartumaverage fasting plasma glucose
Maternal average plasma glucose, Post-cibum24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, 4-12 weeks postpartumaverage plasma glucose, Post-cibum
Postpartum weight retention4-12 weeks postpartumthe weight change from pre-pregnancy to a period postpartum
Insulin medications24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, 4-12 weeks postpartumdosage and insulin form
Hypertensive disorders in pregnancy24-32 weeks of pregnancy, 33 weeks of pregnancy to before deliveryNumber of Participants with preeclampsia-eclampsia or gestational hypertension
Cesarean Section4-12 weeks postpartumNumber of Participants with Cesarean Section
Exercise Frequency24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, 4-12 weeks postpartumNumber of exercises per week.
Health behavior change of glycemic control Scale24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, 4-12 weeks postpartumA 3-item Likert scale based on the Transtheoretical model, including self-monitoring of glucose level, diet and physical activity. Each item scores from 0-4. A higher score means closer to the action or maintenance stage.
Health Belief of glycemic control Scale24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, 4-12 weeks postpartumA 21-item Likert scale based on the Health Belief model includes 5 categories: perceived susceptibility, perceived severity, perceived benefits, perceived barriers and self-efficacy. Each item scores from 0-4. A higher score means higher the individual's beliefs about preventing diseases or maintaining health in perceived susceptibility, perceived severity, perceived benefits and self-efficacy categories. A higher score means higher the individual's barriers to preventing diseases or maintaining health in the perceived barriers category.
Quality of life assessment24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, 4-12 weeks postpartumWorld Health Organization Quality-of-Life Scale:BREF Taiwan Version The scale evaluates four domains of quality of life ("Physical Health," "Psychological Health," "Social Relationships," and "Environment"), and contains four other questions :overall perception of quality of life, general health, dietary ,feel respected. Every domain scores from 4-20. Higher scores mean a better quality of life.
Glucose monitoring satisfaction Scale33 weeks of pregnancy to before deliverySatisfaction of using continuous glucose monitoring (CGM) or blood glucose meters (BGM) access by Likert scale. A 4-item Likert scale includes 4 categories: ease of use, painful, convenience and overall satisfaction. Each item scores from 1-5. A higher score means lower satisfaction.
Perceived benefits and barriers of CGM33 weeks of pregnancy to before deliveryBenefits of CGM (BenCGM) and Burdens of CGM (BurCGM) Questionnaires. A 16-item Likert scale includes 2 categories: benefits of CGM and burdens of CGM. Each item scores from 1-5. A higher score means a higher benefit in benefit of CGM category. A higher score means higher burdens in burdens of CGM category.

Countries

Taiwan

Contacts

CONTACTHUNG-HUI CHEN, PhD
hunghuichen@ntu.edu.tw886-2-2394-7109
PRINCIPAL_INVESTIGATORHUNG-HUI CHEN, PhD

National Taiwan University Hostiptal

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 23, 2026